The diagnosis and management of low-grade dysplasia (LGD) in the setting of Barrett’s esophagus continues to challenge physicians. Interobserver variability among pathologists remains high, and clinicians lack accurate models to predict those at risk of progressing to high-grade dysplasia and esophageal adenocarcinoma. Radiofrequency ablation (RFA) offers a safe and effective treatment option for LGD with acceptable risks, given the unpredictable natural course of the disease. Although current evidence suggests that RFA is cost-effective, long-term data is not yet available. However, patients experience an improvement in disease-specific health-related quality of life. Therefore, RFA should be considered in all patients with LGD.
This is a preview of subscription content, log in to check access.
Vieth M. Low-grade dysplasia in Barrett’s esophagus – an innocent bystander? Contra. Endoscopy. 2007;39:647–9.CrossRefGoogle Scholar
Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–30.CrossRefGoogle Scholar
Kerkhof M, van Dekken H, Steyerberg EW, et al. Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology. 2007;50:920–7.CrossRefGoogle Scholar
Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American college of G. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50; quiz 1.CrossRefGoogle Scholar
Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–88.CrossRefGoogle Scholar
Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141:460–8.CrossRefGoogle Scholar
Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311:1209–17.CrossRefGoogle Scholar
Orman ES, Kim HP, Bulsiewicz WJ, et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett’s esophagus with radiofrequency ablation. Am J Gastroenterol. 2013;108:187–95; quiz 96.CrossRefGoogle Scholar
Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245–55.CrossRefGoogle Scholar
Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2012;143:567–75.CrossRefGoogle Scholar
Shaheen NJ, Peery AF, Hawes RH, et al. Quality of life following radiofrequency ablation of dysplastic Barrett’s esophagus. Endoscopy. 2010;42:790–9.CrossRefGoogle Scholar